+53%

est. 2Y upside i

Healthcare

Autoimmune conditions are rising faster than any other disease, now affecting over 50 million Americans. Yet they remain misunderstood, underdiagnosed, and overlooked. WellTheory is here to change that with a new kind of care that’s personalized, rooted in science, powered by AI, and delivered with compassion. We help people reduce symptoms, feel better, and live fuller lives — while helping employers and payors reduce their spend.

Rank

#1266

Sector

Digital Health

Est. Liquidity

~5Y

Data Quality

Data: Low

WellTheory offers high potential upside (53% expected) but with extreme uncertainty due to missing financials and fierce competition.

Last updated: July 3, 2026

Bull (25%)+246%

AI-driven differentiation sustains high growth and multiple expansion to 10x, yielding exit value of $650M. Competitors fail to erode market share as WellTheory's outcome data drives enterprise wins.

Base (35%)+38%

Growth decelerates to ~225% by year 2, and revenue multiple converges to 4x (public comp average), implying $260M exit. Moderate dilution from a $20M follow-on round reduces net upside.

Bear (40%)-55%

Incumbent Teladoc and big tech entry compress multiple to 2x; exit at $130M leaves only $84.7M for common after $45.3M preference. Additional dilution from down-round destroys further value.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

3020%

Total funding of $45.3M represents 30% of assumed $150M valuation, creating high preference overhang.

Dilution Risk

moderate

With $19M raised recently and moderate capital intensity, a follow-on round within 2 years is likely, causing 15-25% dilution.

Secondary Liquidity

none

No secondary market trades reported; liquidity tied to IPO or acquisition, likely 5+ years out.

Questions to Ask at the Interview

Strategic questions based on WellTheory's data — designed to show you've done your homework.

  • 1

    “How does WellTheory's AI workflow differentiate from Teladoc's virtual care platform?”

  • 2

    “What is the current mix of B2B vs D2C revenue and how will that evolve?”

  • 3

    “Given the $45M total funding and early stage, how should I think about dilution risk from future rounds?”

Community

Valuation Sentiment

Our model estimates +53% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.